AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9164221 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-dose chemotherapy regimen with rhGM-CSF (cyclophosphamide 1,800 mg/m2, 4'-epidoxorubicin 60 mg/m2, etoposide 330 mg/m2, cisplatin 120 mg/m2, plus rhGM-CSF 5 micrograms/kg daily for 10 days)
Number of subjects: 125
Study 9164221 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose chemotherapy regimen (cyclophosphamide 1,200 mg/m2, 4'-epidoxorubicin 40 mg/m2, etoposide 225 mg/m2, cisplatin 100 mg/m2)
Number of subjects: 125
Study 9164221 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-dose plus rhGM-CSF group
Number of subjects: 125
Study 8425987 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk deciles 9 and 10
Number of subjects: 1612
Study 8425987 — intervention group
Group type: COMPARATOR
Intervention: Risk deciles 1 and 2
Number of subjects: 1612
Study 8425987 — intervention group
Group type: EXPERIMENTAL
Intervention: Total study group
Number of subjects: 1612
Study 2221511 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloropromazine 12.5 mg IV (max 37.5 mg)
Number of subjects: 76
Study 2221511 — intervention group
Group type: COMPARATOR
Intervention: Dihydroergotamine 1 mg IV (repeated after 30 minutes if inadequate response)
Number of subjects: 76
Study 2221511 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine 50 mg IV (max total dose of 150 mg)
Number of subjects: 76
Study 589919 — intervention group
Group type: EXPERIMENTAL
Intervention: Arachis oil emulsion
Number of subjects: 450
Study 589919 — intervention group
Group type: EXPERIMENTAL
Intervention: Chocolate-Sorbitol preparation
Number of subjects: 450
Study 589919 — intervention group
Group type: EXPERIMENTAL
Intervention: 46 g of milk chocolate
Number of subjects: 450
Study 589919 — intervention group
Group type: EXPERIMENTAL
Intervention: 26 g of milk chocolate
Number of subjects: 450
Study 31074333 — intervention group
Group type: EXPERIMENTAL
Intervention: Stratified randomization procedures
Number of subjects: 0
Study 31074333 — intervention group
Group type: EXPERIMENTAL
Intervention: Weighted t test under misclassification
Number of subjects: 0
Study 31074333 — intervention group
Group type: EXPERIMENTAL
Intervention: Additive bias model combining selection bias and time‐trend bias
Number of subjects: 0
Study 30332895 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory Work Therapy
Number of subjects: 48
Study 27786358 — intervention group
Group type: EXPERIMENTAL
Intervention: Calling the patient's name
Number of subjects: 101
Study 27786358 — intervention group
Group type: COMPARATOR
Intervention: Control group (general term)
Number of subjects: 101
Study 25830422 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 1044
Study 25830422 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 1044
Study 23152373 — intervention group
Group type: EXPERIMENTAL
Intervention: Colesevelam 3.75 g/day
Number of subjects: 209
Study 23152373 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 209
Study 21778599 — intervention group
Group type: EXPERIMENTAL
Intervention: Overpressed ceramics
Number of subjects: 0
Study 21778599 — intervention group
Group type: EXPERIMENTAL
Intervention: Layered ceramics
Number of subjects: 0
Study 21778599 — intervention group
Group type: EXPERIMENTAL
Intervention: Layered ceramics (LV)
Number of subjects: 0
Study 21778599 — intervention group
Group type: EXPERIMENTAL
Intervention: Layered ceramics (LC)
Number of subjects: 0
Study 19428394 — intervention group
Group type: EXPERIMENTAL
Intervention: Reboxetine (RBX)
Number of subjects: 0
Study 19428394 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16886238 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV grading and staging using the Batts and Ludwig schema
Number of subjects: 312
Study 16886238 — intervention group
Group type: EXPERIMENTAL
Intervention: ACR global grading using the 1997 Banff schema
Number of subjects: 312
Study 16886238 — intervention group
Group type: EXPERIMENTAL
Intervention: Rejection activity index scoring of ACR
Number of subjects: 312
Study 15685825 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine in combination with paclitaxel
Number of subjects: 0
Study 15685825 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Number of subjects: 0
Study 11723016 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (75 mg/d) for 7 days
Number of subjects: 24
Study 11723016 — intervention group
Group type: COMPARATOR
Intervention: Pl(A2) carriers (no aspirin effect)
Number of subjects: 24
Study 11723016 — intervention group
Group type: EXPERIMENTAL
Intervention: Pl(A1A1) subjects (after aspirin ingestion)
Number of subjects: 24
Study 11723016 — intervention group
Group type: COMPARATOR
Intervention: Pl(A2) carriers (after aspirin ingestion)
Number of subjects: 24
Study 9220211 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole oral solution (200 mg once daily)
Number of subjects: 162
Study 9220211 — intervention group
Group type: COMPARATOR
Intervention: Clotrimazole troches (10 mg five times daily)
Number of subjects: 162
Study 8253932 — intervention group
Group type: EXPERIMENTAL
Intervention: Percoll separation
Number of subjects: 0
Study 3552007 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent positive pressure ventilation (IPPV) with nitrous oxide in oxygen facilitated by atracurium 0.5 mg kg‐1
Number of subjects: 50
Study 3552007 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous ventilation (SV) technique with halothane and nitrous oxide in oxygen
Number of subjects: 50
Study 29699816 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight gain prevention strategies (small changes to diet and physical activity)
Number of subjects: 524
Study 29699816 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight gain prevention strategies (large changes)
Number of subjects: 524
Study 29699816 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 524
Study 27524193 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-channel FES treatment based on normal gait pattern
Number of subjects: 58
Study 27524193 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-channel FES treatment
Number of subjects: 58
Study 27524193 — intervention group
Group type: COMPARATOR
Intervention: Placebo electrical group
Number of subjects: 58
Study 27524193 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (four-channel, single-channel, placebo)
Number of subjects: 58
Study 27524193 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-channel FES group
Number of subjects: 58
Study 25012235 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted, theory‐ and evidence‐informed implementation intervention including local stakeholder meetings, identification of nursing and medical opinion leaders, a train‐the‐trainer day, and standardized education and interactive workshops over 3 months.
Number of subjects: 1020
Study 25012235 — intervention group
Group type: COMPARATOR
Intervention: Passive dissemination of clinical practice guidelines (control group).
Number of subjects: 1020
Study 23729106 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergic rhinitis and nasal polyps (SP-D and IL-16 expression)
Number of subjects: 45
Study 23729106 — intervention group
Group type: COMPARATOR
Intervention: Control group (inferior turbinate mucosa)
Number of subjects: 45
Study 23729106 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergic rhinitis
Number of subjects: 45
Study 23729106 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal polyps
Number of subjects: 45
Study 20089454 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyl-cysteine (NAC) 1.2 g/d for 5 days starting at day 3 of the cycle for 12 consecutive cycles
Number of subjects: 60
Study 20089454 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 5 days starting at day 3 of the cycle for 12 consecutive cycles
Number of subjects: 60
Study 18166533 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted, community‐wide intervention including physician behavior‐change strategy, guideline dissemination, small‐group education, updates, educational materials, and prescribing feedback.
Number of subjects: 223135
Study 18166533 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted, community‐wide intervention
Number of subjects: 223135
Study 18166533 — intervention group
Group type: COMPARATOR
Intervention: None (baseline data)
Number of subjects: 223135
Study 16054578 — intervention group
Group type: EXPERIMENTAL
Intervention: Active medication
Number of subjects: 0
Study 16054578 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12849770 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemispherectomy patients
Number of subjects: 22
Study 12849770 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 22
Study 10372705 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-677 (25 mg daily for 8 weeks)
Number of subjects: 24
Study 10372705 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 12)
Number of subjects: 24
Study 8879912 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy for bulimia nervosa
Number of subjects: 114
Study 8879912 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of mood disorder
Number of subjects: 114
Study 8879912 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of anxiety disorder
Number of subjects: 114
Study 1906042 — intervention group
Group type: EXPERIMENTAL
Intervention: Long course of ampicillin (7 days)
Number of subjects: 91
Study 1906042 — intervention group
Group type: EXPERIMENTAL
Intervention: Short course of ampicillin (three doses)
Number of subjects: 91
Study 1906042 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 6349401 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin ethylsuccinate
Number of subjects: 65
Study 6349401 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 30761509 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol + Donepezil
Number of subjects: 36
Study 30761509 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Donepezil
Number of subjects: 36
Study 30114721 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical muscle stimulation (EMS)
Number of subjects: 20
Study 27685609 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite fluoride intervention (varnish with 22,600 p.p.m. fluoride, toothbrush, toothpaste with 1450 p.p.m. fluoride, and prevention advice every 6 months for 3 years)
Number of subjects: 1248
Study 27685609 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite fluoride intervention
Number of subjects: 1248
Study 27685609 — intervention group
Group type: COMPARATOR
Intervention: Control group (prevention advice alone)
Number of subjects: 1248
Study 27685609 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1248
Study 24515422 — intervention group
Group type: EXPERIMENTAL
Intervention: Community health worker intervention
Number of subjects: 446
Study 22314392 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (exact dosage and duration not specified)
Number of subjects: 63
Study 22314392 — intervention group
Group type: COMPARATOR
Intervention: Recall of symptoms
Number of subjects: 63
Study 20140275 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacillus coagulans GBI‐30, 6086
Number of subjects: 52
Study 20140275 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 17521243 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine
Number of subjects: 0
Study 17521243 — intervention group
Group type: COMPARATOR
Intervention: Telmisartan
Number of subjects: 0
Study 17521243 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of telmisartan and nisoldipine
Number of subjects: 0
Study 15186950 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg
Number of subjects: 27
Study 15186950 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg
Number of subjects: 27
Study 15186950 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg
Number of subjects: 27
Study 11777359 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of oral prednisone per day
Number of subjects: 81
Study 11777359 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 9696213 — intervention group
Group type: EXPERIMENTAL
Intervention: Step-down regimen with FSH
Number of subjects: 0
Study 9696213 — intervention group
Group type: COMPARATOR
Intervention: Standard protocol
Number of subjects: 0
Study 8122593 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril after angioplasty
Number of subjects: 653
Study 8122593 — intervention group
Group type: COMPARATOR
Intervention: Static criterion of > 50% diameter stenosis at follow-up
Number of subjects: 653
Study 8122593 — intervention group
Group type: COMPARATOR
Intervention: Dynamic criteria of > or = 0.40 or > or = 0.72 mm change in minimal lumen diameter
Number of subjects: 653
Study 8122593 — intervention group
Group type: COMPARATOR
Intervention: Percentage diameter stenosis measurements
Number of subjects: 653
Study 2764533 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoperazone (CPZ)
Number of subjects: 24
Study 2764533 — intervention group
Group type: COMPARATOR
Intervention: Oral neomycin-erythromycin
Number of subjects: 24
Study 2764533 — intervention group
Group type: COMPARATOR
Intervention: No antibiotics
Number of subjects: 24
Study 1026543 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam 20 mg
Number of subjects: 0
Study 1026543 — intervention group
Group type: COMPARATOR
Intervention: Amylobarbitone sodium 200 mg
Number of subjects: 0
Study 31564410 — intervention group
Group type: EXPERIMENTAL
Intervention: [11C]telmisartan with predosing of 80 mg telmisartan (two 40 mg Micardis® tablets)
Number of subjects: 8
Study 31564410 — intervention group
Group type: COMPARATOR
Intervention: [11C]telmisartan without predosing
Number of subjects: 8
Study 31564410 — intervention group
Group type: EXPERIMENTAL
Intervention: [11C]telmisartan with predosing of 80 mg telmisartan
Number of subjects: 8
Study 28153828 — intervention group
Group type: EXPERIMENTAL
Intervention: CZP+MTX
Number of subjects: 159
Study 28153828 — intervention group
Group type: EXPERIMENTAL
Intervention: CZP+MTX→MTX
Number of subjects: 159
Study 28153828 — intervention group
Group type: EXPERIMENTAL
Intervention: CZP
Number of subjects: 159
Study 28153828 — intervention group
Group type: COMPARATOR
Intervention: CZP+MTX and PBO+MTX
Number of subjects: 159
Study 25494952 — intervention group
Group type: EXPERIMENTAL
Intervention: VR simulator
Number of subjects: 8
Study 25494952 — intervention group
Group type: COMPARATOR
Intervention: Conventional training
Number of subjects: 8
Study 23758821 — intervention group
Group type: EXPERIMENTAL
Intervention: Corifollitropin alfa or rFSH treatment flexibility options
Number of subjects: 0
Study 23758821 — intervention group
Group type: COMPARATOR
Intervention: Starting ovarian stimulation on cycle day 2
Number of subjects: 0
Study 23758821 — intervention group
Group type: COMPARATOR
Intervention: Receiving hCG on the day the hCG criterion was met
Number of subjects: 0
Study 23758821 — intervention group
Group type: COMPARATOR
Intervention: Receiving rFSH on the day of hCG administration
Number of subjects: 0
Study 23758821 — intervention group
Group type: COMPARATOR
Intervention: Reduced versus fixed-dose of rFSH from day 8
Number of subjects: 0
Study 20737175 — intervention group
Group type: EXPERIMENTAL
Intervention: TAI using lipiodol (n = 15)
Number of subjects: 45
Study 20737175 — intervention group
Group type: EXPERIMENTAL
Intervention: TAI using DSM (n = 15)
Number of subjects: 45
Study 20737175 — intervention group
Group type: EXPERIMENTAL
Intervention: TAI using lipiodol and DSM (n = 15)
Number of subjects: 45
Study 18086142 — intervention group
Group type: EXPERIMENTAL
Intervention: ParaPost/CoJet
Number of subjects: 90
Study 18086142 — intervention group
Group type: EXPERIMENTAL
Intervention: FibreKleer/AlOxide
Number of subjects: 90
Study 18086142 — intervention group
Group type: EXPERIMENTAL
Intervention: ParaPost/AlOxide
Number of subjects: 90
Study 18086142 — intervention group
Group type: EXPERIMENTAL
Intervention: FibreKleer/CoJet
Number of subjects: 90
Study 18086142 — intervention group
Group type: EXPERIMENTAL
Intervention: FibreKor/AlOxide
Number of subjects: 90
Study 18086142 — intervention group
Group type: EXPERIMENTAL
Intervention: ParaPost/Unroughened
Number of subjects: 90
Study 18086142 — intervention group
Group type: EXPERIMENTAL
Intervention: FibreKor/CoJet
Number of subjects: 90
Study 18086142 — intervention group
Group type: EXPERIMENTAL
Intervention: FibreKor/Unroughened
Number of subjects: 90
Study 18086142 — intervention group
Group type: EXPERIMENTAL
Intervention: FibreKleer/Unroughened
Number of subjects: 90
Study 17320192 — intervention group
Group type: EXPERIMENTAL
Intervention: Maprotiline
Number of subjects: 23
Study 17320192 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 23
Study 16200447 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabeculectomy (TE)
Number of subjects: 22
Study 16200447 — intervention group
Group type: EXPERIMENTAL
Intervention: Viscocanalostomy (VCO)
Number of subjects: 22
Study 11359224 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mL NS x 1 (n = 10)
Number of subjects: 33
Study 11359224 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mL NS x 2 (n = 12)
Number of subjects: 33
Study 11359224 — intervention group
Group type: COMPARATOR
Intervention: Control (n = 11)
Number of subjects: 33
Study 9387180 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone oil
Number of subjects: 34
Study 9387180 — intervention group
Group type: COMPARATOR
Intervention: SF6
Number of subjects: 34
Study 7524278 — intervention group
Group type: EXPERIMENTAL
Intervention: estramustine phosphate
Number of subjects: 62
Study 7524278 — intervention group
Group type: COMPARATOR
Intervention: non-steroidal symptomatic treatment
Number of subjects: 62
Study 3063290 — intervention group
Group type: EXPERIMENTAL
Intervention: Active vitamin D (alphacalcidol), 1 microgram daily
Number of subjects: 33
Study 3063290 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 31121100 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Number of subjects: 143
Study 31121100 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise training
Number of subjects: 143
Study 31121100 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exercise training
Number of subjects: 143
Study 31121100 — intervention group
Group type: COMPARATOR
Intervention: Diet-only control
Number of subjects: 143
Study 31579037 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquablation using the Aquabeam system (PROCEPT BioRobotics)
Number of subjects: 0
Study 31579037 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquablation
Number of subjects: 0
Study 31579037 — intervention group
Group type: COMPARATOR
Intervention: TURP (Transurethral Resection of the Prostate)
Number of subjects: 0
Study 29233906 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep restriction (SR) - 50% of habitual sleep duration for 2 nights
Number of subjects: 10
Study 29233906 — intervention group
Group type: COMPARATOR
Intervention: Control (CON) - habitual sleep for 2 nights
Number of subjects: 10
Study 23265332 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiographic complete revascularization (CR) in PCI arm (52.8%)
Number of subjects: 1800
Study 23265332 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiographic complete revascularization (CR) in CABG arm (66.9%)
Number of subjects: 1800
Study 23265332 — intervention group
Group type: COMPARATOR
Intervention: Incomplete revascularization (ICR)
Number of subjects: 1800
Study 23265332 — intervention group
Group type: COMPARATOR
Intervention: Presence of total occlusions (TO)
Number of subjects: 1800
Study 21235416 — intervention group
Group type: EXPERIMENTAL
Intervention: Korean red ginseng (KRG) 3 g/day
Number of subjects: 80
Study 21235416 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 21235416 — intervention group
Group type: EXPERIMENTAL
Intervention: KRG and Placebo
Number of subjects: 80
Study 18698316 — intervention group
Group type: EXPERIMENTAL
Intervention: Betahistine 48 mg (n=23)
Number of subjects: 281
Study 18698316 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=25)
Number of subjects: 281
Study 17070197 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluation while off any estrogen therapy
Number of subjects: 130
Study 17070197 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiologic transdermal E(2) therapy
Number of subjects: 130
Study 12590030 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily tramadol tablets 150 mg
Number of subjects: 134
Study 12590030 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily tramadol tablets 200 mg
Number of subjects: 134
Study 12590030 — intervention group
Group type: COMPARATOR
Intervention: Normal release tramadol capsules 50 mg 8-hourly
Number of subjects: 134
Study 10767191 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI staging before radiotherapy
Number of subjects: 143
Study 10767191 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI features (tumour size, circumferential tumour extent, presence of hydronephrosis)
Number of subjects: 143
Study 10767191 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI T stage
Number of subjects: 143
Study 8838693 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-exposure to both internal (interoceptive) and external cues
Number of subjects: 26
Study 8838693 — intervention group
Group type: COMPARATOR
Intervention: Self-exposure to external cues only
Number of subjects: 26
Study 1441953 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous irrigation with Ringer solution during cement curing
Number of subjects: 19
Study 1441953 — intervention group
Group type: COMPARATOR
Intervention: No irrigation (control group)
Number of subjects: 19
Study 3913478 — intervention group
Group type: EXPERIMENTAL
Intervention: Mianserin (30 mg)
Number of subjects: 0
Study 3913478 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitryptiline (75 mg)
Number of subjects: 0
Study 3913478 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine (75 mg)
Number of subjects: 0
Study 3913478 — intervention group
Group type: EXPERIMENTAL
Intervention: Maprotiline (75 mg)
Number of subjects: 0
Study 3913478 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31873085 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine cloudiness
Number of subjects: 17
Study 31873085 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased discriminatory scale for urine cloudiness (turbidity)
Number of subjects: 17